ASH Meeting on Hematologic Malignancies
September 10 - 11, 2021
The ASH Meeting on Hematologic Malignancies features the top experts in the field, comprehensive clinical content, and the opportunity to interact with colleagues. The 2021 meeting will be offered online as a virtual meeting. Participation in the meeting grants participants an opportunity to hear experts present cutting-edge scientific data, provide out-of-the-box treatment approaches, and answer challenging patient care questions during topic-based panel discussions.
The program content is structured with "How I Treat" presentations that showcase speakers’ evidence-based treatment approaches. Learn how new data can be translated into new strategies for diagnosis and treatment, find out what to do in cases where there is no data, and gain knowledge that can help you make an immediate impact on your practice.
Hear exciting updates in each of the core malignancies, including:
- Myelodysplastic syndromes
- Myeloproliferative neoplasms
- Anjali Advani, MD, Cleveland Clinic
- S. Vincent Rajkumar, MD, Mayo Clinic
- Sonali Smith, MD, University of Chicago
Program Planning Committee
- Stephen Ansell, MD, Mayo Clinic
- Partow Kebriaei, MD, MD Anderson Cancer Center
- John Mascarenhas, MD, Mount Sinai Medical School
ASH would like to acknowledge the following companies for the educational grants provided in support of the 2021 ASH Meeting on Hematologic Malignancies:
- Astellas Pharma US, Inc.
- Bristol Myers Squibb
- Gilead Sciences, Inc.
- Incyte Corporation
- Jazz Pharmaceuticals, Inc.
- Kite Pharma, Inc.
- Merck & Co., Inc.
- Novartis Pharmaceuticals
- Pfizer Inc.
- Takeda Oncology